Namenda

This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.

Forest said to be interested in $3bn Aptalis acquisition

US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at

Latest news

Lundbeck and Otsuka take Alzheimer's drug into phase III

Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs
Lexapro generics hammer Forest Labs' Q3 results

On the plus side, Alzheimer's drug Namenda (memantine) achieved a 9 per cent hike in sales to $368m, while antihypertensive Bystolic (nebivolol) was up almost 30 per cent to $106m. ... With Lexapro now completely genericised we have a bright future with
Forest's net income down for Q3

He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following
Forest Laboratories earnings rise

Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.
Lifting the fog

Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist

More from news
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Pharma deals during January 2014

Not disclosed. Adamas. Forest. Completion of studies for the NDA of a fixed dosed combination of Namenda and donepezil, Forest has exclusive US commercialisation rights.
Pharma deals during November 2012

Development / commercialisation. Fixed dose combination of Namenda and donepezil for AD.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Client Services Director - Med Comms: Great salary and bebefits

Delivery Manager/ Head of Delivery – Executive Search: Neg

Client Services Director – Healthcare Advertising - London: Neg

Senior Account Manager: Competitive salary commensurate with experience

Home based, Senior Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Business Unit Head, Medical Communications, London: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Editorial Director – Medical Education (MedComms): Neg

Home based, Chief Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....